We found that PCa patients with the AR (CAG)M + APEX1 c.444TT/GG combination had an over 2.5-fold increased risk of undergoing biochemical relapse within 6 years compared to patients with other genotypes. The gene discussed is AR; the disease is posterior cortical atrophy.